BioTuesdays

Tag - ALDX

BTIG starts Aldeyra Therapeutics at buy; PT $29

BTIG initiated coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and $29 price target. The stock closed at $6.86 on Oct. 15. Aldeyra is targeting reactive aldehyde species (RASP) for a range of...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.